We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

83 hedge funds and large institutions have $365M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 15

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

53% more capital invested

Capital invested by funds: $239M → $365M (+$126M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

9% more funds holding

Funds holding: 76 → 83 (+7)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $173K

Holders
83
Holders Change
+7
Holders Change %
+9.21%
% of All Funds
1.88%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
18
Increased
37
Reduced
15
Closed
11
Calls
–
Puts
$173K
Net Calls
-$173K
Net Calls Change
-$173K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.41M
2
PHS
PFM Health Sciences
California
+$5.28M
3
GPP
Great Point Partners
Connecticut
+$4.3M
4
Millennium Management
Millennium Management
New York
+$2.74M
5
JP Morgan Chase
JP Morgan Chase
New York
+$1.77M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.47M
2
AC
Ascend Capital
California
-$2.81M
3
HIM
Hillhouse Investment Management
Cayman Islands
-$2.02M
4
FCMI
Foresite Capital Management II
California
-$1.87M
5
UBS AM
UBS AM
Illinois
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$1.3M +$5.28K +359 +0.4%
BBA
27
Baker Bros. Advisors
New York
$1.27M – – –
VIA
28
Vident Investment Advisory
Georgia
$1.24M +$391K +26,628 +38%
First Manhattan
29
First Manhattan
New York
$994K +$691K +47,000 +152%
OAM
30
Oxford Asset Management
United Kingdom
$966K +$202K +13,771 +23%
Goldman Sachs
31
Goldman Sachs
New York
$788K -$782K -53,175 -46%
AIM
32
ARK Investment Management
Florida
$678K +$362K +24,644 +86%
JGC
33
J. Goldman & Co
New York
$638K +$735K +50,000 New
Morgan Stanley
34
Morgan Stanley
New York
$607K -$709K -48,231 -50%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$585K +$65.7K +4,467 +11%
PCM
36
Parsons Capital Management
Rhode Island
$548K – – –
TAM
37
Tocqueville Asset Management
New York
$548K +$631K +42,950 New
Charles Schwab
38
Charles Schwab
California
$543K +$16.1K +1,092 +3%
Wells Fargo
39
Wells Fargo
California
$534K +$311K +21,127 +102%
USAA
40
United Services Automobile Association
Texas
$473K +$545K +37,100 New
AA
41
ALPS Advisors
Colorado
$454K +$58.3K +3,966 +13%
Russell Investments Group
42
Russell Investments Group
United Kingdom
$421K – – –
Deutsche Bank
43
Deutsche Bank
Germany
$416K +$174K +11,805 +57%
TCIM
44
TIAA CREF Investment Management
New York
$367K -$197K -13,434 -32%
AIMCA
45
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$363K -$39.7K -2,700 -9%
SO
46
STRS Ohio
Ohio
$353K -$200K -13,600 -33%
VEA
47
Virtus ETF Advisers
New York
$344K +$97.8K +6,650 +33%
VFA
48
Virtus Fund Advisers
Connecticut
$344K +$396K +26,948 New
TA
49
Teachers Advisors
New York
$326K +$140K +9,507 +59%
Swiss National Bank
50
Swiss National Bank
Switzerland
$315K +$166K +11,300 +84%
1
2
3 4

JNCE Hedge Fund Activity: Q4 2017 in Review

83 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2017, worth a combined $365M — up 53% from $239M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new JNCE positions and 11 closed out — a net gain of 7 holders — while 37 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $6.41M. The largest seller was Fidelity Investments, cutting an estimated $9.47M.

  • 83 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2017, up from 76 in Q3 2017.
  • Funds reported $365M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2017, up 53% quarter-over-quarter.
  • 18 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2017 and 11 closed out, a net change of +7 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2017 was BlackRock, an estimated $6.41M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2017 was Fidelity Investments, an estimated $9.47M sold.

Based on aggregated 13F filings for Q4 2017.